Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26290
Title: Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.
Austin Authors: Liu, Howard Yu-Hao;Lee, Yoo-Young Dominique;Sridharan, Swetha;Choong, Ee Siang;Le, Hien;Wang, Wei;Khor, Richard ;Chu, Julie;Oar, Andrew;Mott, Rebekah;Smart, Joanne;Jenkins, Trish ;Anderson, Nigel;Cross, Shamira;Loo, Kee Fong;Wigg, Alan;Stuart, Katherine;Pryor, David
Affiliation: Department of Radiation Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
Olivia Newton-John Cancer Wellness and Research Centre
Department of Radiation Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia
Icon Cancer Centre, Gold Coast University Hospital, Gold Coast, Queensland, Australia
Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia
Department of Radiation Oncology, The Crown Princess Mary Cancer Centre, Sydney, New South Wales, Australia
Department of Radiation Oncology, Nepean Cancer Care Centre, Sydney, New South Wales, Australia
Icon Cancer Centre, Greenslopes Hospital, Brisbane, Queensland, Australia
Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
Hepatology and Liver Transplantation Medicine Unit, Flinders Medical Centre, Adelaide, South Australia, Australia
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Radiation Oncology
Issue Date: 22-Apr-2021
metadata.dc.date: 2021-04-22
Publication information: Journal of Medical Imaging and Radiation Oncology 2021; online first: 22 April
Abstract: Stereotactic body radiotherapy (SBRT) is an emerging, therapeutic option in the management of hepatocellular carcinoma (HCC). A multicentre Liver Ablative Stereotactic Radiation (LASR) database was established to provide a collaborative platform for Australian institutions to define the practice of liver SBRT for HCC. This study explores the patterns of SBRT practice amongst Australian institutions. This was a multi-institutional retrospective study of patients treated with SBRT for HCC at 10 institutions between January 2013 and December 2019. Patients' demographics, disease characteristics and SBRT details were evaluated. Three hundred and seventeen patients were evaluated with a median age of 67 years (range, 32-90). Liver cirrhosis was present in 88.6%, baseline Child-Pugh score was A5/6 in 85.1% and B7/8 in 13.2%. Median size of HCC treated was 30 mm (range, 10-280). 63.1% had early-stage disease (Barcelona clinic liver cancer (BCLC) stage 0/A) and 36% had intermediate/advanced-stage disease (BCLC B/C). In 2013/2014, six courses of SBRT were delivered, increasing to 108 in 2019. SBRT was prescribed in five fractions for 71.3% of the cohort. The most common dose fractionation schedule was 40 Gy in five fractions (24.3%). Median biologically effective dose (BED10 ) delivered was 85.5 Gy for early-stage and 60 Gy for intermediate/advanced disease, respectively. The most common prescription range was 100-120 Gy BED10 (32.8%). SBRT utilisation for HCC is increasing in Australia. There was wide variation in size of tumours and disease stages treated, and prescription patterns. Uniform reporting of clinical and dosimetric details are important in refining the role of liver SBRT.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26290
DOI: 10.1111/1754-9485.13184
ORCID: 0000-0002-9902-9529
0000-0003-2574-2476
PubMed URL: 33890425
Type: Journal Article
Subjects: dose fractionation
hepatocellular carcinoma
practice patterns
stereotactic ablative radiotherapy
stereotactic body radiotherapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Jul 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.